



ASX ANNOUNCEMENT

Starpharma licences VivaGel BV to Aspen for ANZ

Melbourne, Australia; 4 March 2016: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced the signing of a License and Supply Agreement with Aspen Pharmacare Australia Pty Ltd for the sales and marketing of VivaGel[®] BV in Australia and New Zealand (ANZ).

VivaGel[®] BV has already been approved for marketing in the European Union as a 7-day therapy for the topical treatment and rapid relief of bacterial vaginosis (BV) including its symptoms and is currently under review in Australia by the Therapeutic Goods Administration (TGA) according to the applicable Australia-EU Mutual Recognition Agreement (MRA). Plans for a regulatory submission in New Zealand are also underway.

Under the License Agreement, Aspen is responsible for all marketing, promotion and local distribution of the product to clinicians and pharmacies, with a product launch targeted for 2016. Starpharma maintains manufacturing rights to VivaGel[®] BV and commercialisation rights in all other territories of the world, many of which are the subject of active negotiations. Starpharma will supply Aspen with VivaGel[®] BV and will receive royalties on net sales. The commercial terms of the agreement remain confidential.

Starpharma's CEO, Dr Jackie Fairley, stated: "We believe Aspen is an ideal sales and marketing partner for VivaGel[®] BV in the Australian and New Zealand markets as they have a proven track record of successfully marketing products in the women's healthcare segment. BV is the world's most common vaginal infection and a significant unmet medical need. We are pleased VivaGel[®] BV, an Australian innovation, will give BV sufferers a new option for management, where few effective alternatives exist."

About Bacterial Vaginosis (BV)

BV is the most common vaginal infection worldwide and the most common cause of abnormal discharge and unpleasant odour in women. BV is associated with an increased risk of pre-term births, miscarriage, and transmission and acquisition of sexually transmitted infections (STIs), including genital herpes and HIV/AIDS. BV is the result of a major imbalance in the types and numbers of bacteria in the vagina resulting in a characteristic odour and discharge.

ABOUT STARPHARMA

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

Starpharma's underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical and medical uses. Starpharma has three core development programs: VivaGel[®] portfolio, DEP[™] drug delivery, and agrochemicals with the Company developing a number of products internally and others via commercial partnerships.

Starpharma's lead products are based on VivaGel® (SPL7013, astodimer sodium), a proprietary dendrimer which has antimicrobial properties. VivaGel® formulated as a water based gel and delivered vaginally now has EU regulatory approval for topical treatment and rapid relief of bacterial vaginosis (BV) and is under clinical development for the prevention of recurrent BV. Starpharma has also signed separate licence agreements with Ansell Limited (ASX:ANN) and Okamoto Industries, Inc., (TSE: JP319280005) to market a value-added, VivaGel® condom. The VivaGel® condom is available for purchase in Australia under Ansell's Lifestyles® Dual Protect™ brand. Ansell manufactures and sells leading condom brands worldwide, including LifeStyles®, ZERO® and SKYN®. Okamoto is the market leader for condoms sold in Japan, which is the world's second largest condom market.

In the wider pharmaceutical field, Starpharma has both partnered and internal programs in Drug Delivery. A number of dendrimer-enhanced or DEP™ versions of existing drugs are under development. The most advanced of these is DEP™ docetaxel, a dendrimer-enhanced version of docetaxel (Taxotere®), which is in clinical development in patients with solid tumours. In preclinical studies DEP™ docetaxel has shown significant tumour-targeting and superior anti-cancer effects across a range of important cancer types including breast, prostate, lung and ovarian tumour, when compared to Taxotere® (docetaxel). AstraZeneca has signed a licensing agreement with Starpharma for the use of its DEP™ drug delivery platform in the development and commercialisation of an AstraZeneca oncology compound, with potential for follow on compounds directed at a defined family of targets.

In agrochemicals Starpharma has a series of partnerships with leading industry players including global leader Adama (formerly Makhteshim Agan) as well as internal programs including an enhanced version of glyphosate (the active ingredient in Roundup®). For more information please visit: www.starpharma.com

ABOUT ASPEN PHARMACARE AUSTRALIA PTY LTD

Aspen Pharmacare Australia Pty Ltd is a subsidiary of Aspen Pharmacare Holdings Ltd, the largest pharmaceutical company listed on the South African stock exchange, the JSE Limited. Aspen is a global supplier of branded and generic pharmaceutical products as well as infant milk nutritionals and consumer healthcare products in selected territories. The Aspen group has 26 manufacturing facilities at 18 sites on 6 continents and more than 10 000 employees. With its extensive basket of products that provide treatment for a broad spectrum of acute and chronic conditions experienced throughout all stages of life, Aspen continues to increase the number of lives benefiting from its products, reaching more than 150 countries across the world.

FOR FURTHER INFORMATION

Media:

Buchan Consulting

Rebecca Wilson

Mob: +61 417 382 391

rwilson@buchanwe.com.au

Gabriella Hold

+61 3 9866 4722

ghold@buchanwe.com.au

Starpharma:

Dr Jackie Fairley, Chief Executive Officer

Nigel Baade, CFO and Company Secretary

+61 3 8532 2704

investor.relations@starpharma.com

www.starpharma.com

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove

incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.